title: Big pharma and the problem of disease inflation.
abstract: Over the course of the past decade, critics have increasingly called attention to the corrosive influence of the pharmaceutical industry on both biomedical research and the practice of medicine. Critics describe the industry's use of ghostwriting and other unethical techniques to expand their markets as evidence that medical science is all-too-frequently subordinated to the goals of corporate profit. While we do not dispute this perspective, we argue that it is imperative to also recognize that the goals of medical science and industry profit are now tightly wed to one another. As a result, medical science now operates to expand disease definitions, lower diagnostic thresholds, and otherwise advance the goals of corporate profit through the redefinition and expansion of what it means to be ill. We suggest that this process has led to a variety of ethical problems that are not fully captured by current critiques of ghostwriting and other troubling practices by the pharmaceutical industry. In our conclusion, we call for physicians, ethicists, and other concerned observers to embrace a more fundamental critique of the relationship between biomedical science and corporate profit.
authors.forename: Joseph M
authors.initials: JM
authors.lastname: Gabriel
authors.forename: Daniel S
authors.initials: DS
authors.lastname: Goldberg
mesh_terms: D002986:Clinical Trials as Topic / Q000941:ethics / Q000639:trends; D004345:Drug Industry / Q000941:ethics* / Q000639:trends; D004992:Ethics, Medical; D004994:Ethics, Pharmacy; D005544:Forecasting; D005607:Fraud / Q000941:ethics / Q000639:trends; D006801:Humans; D040541:Marketing / Q000941:ethics* / Q000639:trends; D062528:Medicalization / Q000941:ethics* / Q000639:trends; D056687:Off-Label Use / Q000941:ethics; D011634:Public Health / Q000941:ethics / Q000639:trends; D014481:United States